胶原交联技术在眼表疾病的研究进展  

Recent advances in collagen cross-linking on treatment of ocular surface disease

作　　者：桂炎香 李青松[1] 莫利娟[1] 赵黎[1] 张斌[1] GUI Yanxiang;LI Qingsong;MO Lijuan(Putuo Hospital,Shanghai University of Traditional Medicine, Shanghai 200062, Chin)

机构地区：[1]上海中医药大学附属普陀医院,上海200062

出　　处：《中国中医眼科杂志》2018年第1期65-68,共4页China Journal of Chinese Ophthalmology

基　　金：上海市医学重点专科-眼科(ZK2015A20);上海市普陀区卫生自主创新科研基金(17-PT-07);上海市普陀区中心医院2016年度院级重点课题(2016301A)

摘　　要：紫外光核黄素胶原交联技术(Collagen cross-linking,CXL)是以核黄素为光敏剂,应用紫外线进行局部照射,介导胶原纤维相互交联,提高机械硬度和生物力学稳定性,从而阻止圆锥角膜等扩张性角膜疾病的一种新的治疗方法。CXL最初用于圆锥角膜,现在眼表疾病中的应用也日益广泛,近年来研究者开始探讨其联合应用的进展以进一步寻找新的突破点。本文对CXL的分类、基本原理、适应症、禁忌症以及在眼表疾病的应用等进行综述。The ultraviolet ray and riboflavin collagen cross-linking（CXL） technique, as a new method to prevent the development of keratoconus, used riboflavin as a photosensitizer, locally irradiated by ultraviolet ray which together mediated collagen cross-linking to each other to improve the mechanical hardness and biomechanical stability. Collagen cross-linking was first applied in keratoconus, and now it is widely used in ocular surface diseases, and more researchers have begun to explore the combined therapy with CXL in order to make breakthrough. In this paper, the classification,basic principles, indications, contraindications of collagen cross-linking,and its application in ocular surface diseases were reviewed.

关 键 词：胶原交联 眼表疾病 应用 

分 类 号：R772[医药卫生—眼科] R777[医药卫生—临床医学]